In response to persistent complaints by a small number of patients about outcome and quality of life following laser-assisted in situ keratomileusis (LASIK), the US Food and Drug Administration (FDA) is considering whether the procedure requires more rigorous oversight.
The FDA announced on October 15 that it was launching the LASIK Quality of Life Collaboration Project. Completion of the 3-phase project, which also involves the Department of Defense and the National Eye Institute, is expected by the end of 2012.
Mitka M. FDA Focuses on Quality-of-Life Issues for Patients Following LASIK Surgery. JAMA. 2009;302(22):2420–2422. doi:10.1001/jama.2009.1763
Customize your JAMA Network experience by selecting one or more topics from the list below.